Stryker Corporation

Creative Biomolecules, Inc.

Curis, Inc.

Genzyme Corporation

Baylor College of Medicine

Genera Istrazivanja D.o.o.

Other

The State University of New York

Ludwig Institute for Cancer Research Limited

Styker Corporation

Perform Biologies, Inc.

Kuber T Sampath

David C Rueger

Charles M Cohen

Slobodan Vukicevic

Hermann Oppermann

Vladimir Katic

Marjorie M Tucker

Brendan Lee

Roger K Khouri

Carl-Henrik Heldin

Kohei Miyazono

Gideon A Rodan

Roy H L Pang

Shun-ichi Harada

Engin Ozkaynak

Peter Ten Dijke

Hidenori Ichijo

Lovorka Grgurevic

Slobodon Vukicevic

John E Smart

Peter C Keck

William D Carlson

Ronald F Tucker

William K Jones

Dennis Higgins

Herman Oppermann

Dorai Haimanti

Alyssa A Shepard

Diana L Griffith

Hideki Nishitoh

Kohsuke Takeda

The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGFβ).

Methods for treating osteogenesis imperfecta

An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof in a range of from 2 to 1000 &#x3bc;g per ml of autologous blood; and hydroxyapatite, tri-calcium phosphate, or a mixture thereof as a compression resistant matrix, the compression resistant matrix being provided in the form of particles having a particle size in a range of from above 74 to 8000 &#x3bc;m. Preferably, a ratio between the compression resistant matrix and the autologous blood coagulum is from 50 to 500 mg of the compression resistant matrix per mL of the autologous blood coagulum.

Autologous bone graft substitute composition comprising bioceramic particles of different geometry

An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects, a method of preparation thereof, and a method of inducing or promoting bone growth by treatment of a bone with an autologous bone graft substitute composition. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof; and a compression resistant matrix selected from the group consisting of a bone autograft, bone allograft, hydroxyapatite, tri-calcium phosphate, and combinations thereof. The autologous blood forms a coagulum gel comprising a fibrin-meshwork reinforced with the compression resistant matrix and containing the osteogenic bone morphogenetic protein which is released over a sustained period.

Autologous bone graft substitute composition

The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF&#x3b2;).

The present invention relates to an Autologous Bone Graft Substitute composition (ABGS) for inducing new bone formation, promoting bone growth and treating of bone defect, a preparation method of the Autologous Bone Graft Substitute composition, and a kit for preparing the Autologous Bone Graft Substitute composition of implant. In a particular aspect, the invention relates to an injectable/extrudable/implantable Autologous Bone Graft Substitute composition for use in treatment of bone defects, inducing new bone formation and promoting bone growth for bone fracture healing, spinal fusions and to repair bone defects in bone reconstructive procedures of orthopedic and oral maxillofacial-dental surgeries.

Autologous bone graft substitute

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-&#x3b2; superfamily of proteins.

Therapies for acute renal failure

Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues in a mammal.

Method and device for repairing the larynx, trachea and other fibrocartilaginous tissues

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-&#x3b2; superfamily of proteins.

Therapies for chronic renal failure

Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci, intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues in a mammal.

Repair of ligament using osteogenic proteins

Method for repairing a defect in an intervertebral disc

Devices and method for repair of larynx, trachea, and other fibrocartilaginous tissues

Growing community of inventors

Holliston, MA, United States of America

Kuber T Sampath